Cytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support
© 2021 The Authors..
It has been postulated that the underlying pathophysiology of COVID-19 is mediated by cytokine storm resulting in a hyperinflammatory state. A similar kind of cytokine-storm has been described in individuals undergoing veno-venous extracorporeal membrane oxygenation (VV ECMO) support. There is therefore concern that initiation of VV ECMO support among COVID19 patients could further exacerbate this dysregulated inflammatory response. In this prospective cohort study, we describe the clinical course and cytokine fluctuations in eight subjects treated with VV ECMO for management of refractory respiratory failure from COVID19. Among all eight patients, cytokine elevations were noted among Interleukin 6 (IL-6), Interleukin 10 (IL-10), and Interleukin 2 Receptor (CD25) soluble (sIL2R). Although further research is necessary, among our cohort of patients it did not appear that initiation of VV ECMO worsened cytokine storm.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Respiratory medicine case reports - 33(2021) vom: 02., Seite 101376 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaman, Kelsey [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 20.09.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.rmcr.2021.101376 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322380359 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322380359 | ||
| 003 | DE-627 | ||
| 005 | 20231225181923.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rmcr.2021.101376 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322380359 | ||
| 035 | |a (NLM)33680800 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaman, Kelsey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Authors. | ||
| 520 | |a It has been postulated that the underlying pathophysiology of COVID-19 is mediated by cytokine storm resulting in a hyperinflammatory state. A similar kind of cytokine-storm has been described in individuals undergoing veno-venous extracorporeal membrane oxygenation (VV ECMO) support. There is therefore concern that initiation of VV ECMO support among COVID19 patients could further exacerbate this dysregulated inflammatory response. In this prospective cohort study, we describe the clinical course and cytokine fluctuations in eight subjects treated with VV ECMO for management of refractory respiratory failure from COVID19. Among all eight patients, cytokine elevations were noted among Interleukin 6 (IL-6), Interleukin 10 (IL-10), and Interleukin 2 Receptor (CD25) soluble (sIL2R). Although further research is necessary, among our cohort of patients it did not appear that initiation of VV ECMO worsened cytokine storm | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Interleukins | |
| 650 | 4 | |a Respiratory insufficiency | |
| 700 | 1 | |a Azmy, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Chichra, Astha |e verfasserin |4 aut | |
| 700 | 1 | |a Britto-Leon, Clemente |e verfasserin |4 aut | |
| 700 | 1 | |a Price, Christina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory medicine case reports |d 2012 |g 33(2021) vom: 02., Seite 101376 |w (DE-627)NLM249522950 |x 2213-0071 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2021 |g day:02 |g pages:101376 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmcr.2021.101376 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2021 |b 02 |h 101376 | ||